Literature DB >> 10632234

Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia.

L A Glantz1, D A Lewis.   

Abstract

BACKGROUND: The pathophysiological characteristics of schizophrenia appear to involve altered synaptic connectivity in the dorsolateral prefrontal cortex. Given the central role that layer 3 pyramidal neurons play in corticocortical and thalamocortical connectivity, we hypothesized that the excitatory inputs to these neurons are altered in subjects with schizophrenia.
METHODS: To test this hypothesis, we determined the density of dendritic spines, markers of excitatory inputs, on the basilar dendrites of Golgi-impregnated pyramidal neurons in the superficial and deep portions of layer 3 in the dorsolateral prefrontal cortex (area 46) and in layer 3 of the primary visual cortex (area 17) of 15 schizophrenic subjects, 15 normal control subjects, and 15 nonschizophrenic subjects with a psychiatric illness (referred to as psychiatric subjects).
RESULTS: There was a significant effect of diagnosis on spine density only for deep layer 3 pyramidal neurons in area 46 (P = .006). In the schizophrenic subjects, spine density on these neurons was decreased by 23% and 16% compared with the normal control (P = .004) and psychiatric (P = .08) subjects, respectively. In contrast, spine density on neurons in superficial layer 3 in area 46 (P = .09) or in area 17 (P = .08) did not significantly differ across the 3 subject groups. Furthermore, spine density on deep layer 3 neurons in area 46 did not significantly (P = .81) differ between psychiatric subjects treated with antipsychotic agents and normal controls.
CONCLUSION: This region- and disease-specific decrease in dendritic spine density on dorsolateral prefrontal cortex layer 3 pyramidal cells is consistent with the hypothesis that the number of cortical and/or thalamic excitatory inputs to these neurons is altered in subjects with schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10632234     DOI: 10.1001/archpsyc.57.1.65

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  596 in total

Review 1.  Update on childhood-onset schizophrenia.

Authors:  J L Rapoport; G Inoff-Germain
Journal:  Curr Psychiatry Rep       Date:  2000-10       Impact factor: 5.285

2.  Gene expression profiling reveals alterations of specific metabolic pathways in schizophrenia.

Authors:  Frank A Middleton; Karoly Mirnics; Joseph N Pierri; David A Lewis; Pat Levitt
Journal:  J Neurosci       Date:  2002-04-01       Impact factor: 6.167

3.  Cortical thickness and surface area in neonates at high risk for schizophrenia.

Authors:  Gang Li; Li Wang; Feng Shi; Amanda E Lyall; Mihye Ahn; Ziwen Peng; Hongtu Zhu; Weili Lin; John H Gilmore; Dinggang Shen
Journal:  Brain Struct Funct       Date:  2014-11-02       Impact factor: 3.270

4.  Chronic administration of the neurotrophic agent cerebrolysin ameliorates the behavioral and morphological changes induced by neonatal ventral hippocampus lesion in a rat model of schizophrenia.

Authors:  Rubén Antonio Vázquez-Roque; Brenda Ramos; Carolina Tecuatl; Ismael Juárez; Anthony Adame; Fidel de la Cruz; Sergio Zamudio; Raúl Mena; Edward Rockenstein; Eliezer Masliah; Gonzalo Flores
Journal:  J Neurosci Res       Date:  2011-09-19       Impact factor: 4.164

Review 5.  GABAergic interneuron origin of schizophrenia pathophysiology.

Authors:  Kazu Nakazawa; Veronika Zsiros; Zhihong Jiang; Kazuhito Nakao; Stefan Kolata; Shuqin Zhang; Juan E Belforte
Journal:  Neuropharmacology       Date:  2011-01-26       Impact factor: 5.250

Review 6.  Defects in Bioenergetic Coupling in Schizophrenia.

Authors:  Courtney R Sullivan; Sinead M O'Donovan; Robert E McCullumsmith; Amy Ramsey
Journal:  Biol Psychiatry       Date:  2017-10-24       Impact factor: 13.382

Review 7.  Remodeling of axo-spinous synapses in the pathophysiology and treatment of depression.

Authors:  P Licznerski; R S Duman
Journal:  Neuroscience       Date:  2012-10-02       Impact factor: 3.590

8.  DNA-methyltransferase 1 mRNA is selectively overexpressed in telencephalic GABAergic interneurons of schizophrenia brains.

Authors:  M Veldic; H J Caruncho; W S Liu; J Davis; R Satta; D R Grayson; A Guidotti; E Costa
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-18       Impact factor: 11.205

9.  Effects of davunetide on N-acetylaspartate and choline in dorsolateral prefrontal cortex in patients with schizophrenia.

Authors:  L Fredrik Jarskog; Zhengchao Dong; Alayar Kangarlu; Tiziano Colibazzi; Ragy R Girgis; Lawrence S Kegeles; Deanna M Barch; Robert W Buchanan; John G Csernansky; Donald C Goff; Michael P Harms; Daniel C Javitt; Richard Se Keefe; Joseph P McEvoy; Robert P McMahon; Stephen R Marder; Bradley S Peterson; Jeffrey A Lieberman
Journal:  Neuropsychopharmacology       Date:  2013-01-16       Impact factor: 7.853

10.  Dysbindin-1 contributes to prefrontal cortical dendritic arbor pathology in schizophrenia.

Authors:  Glenn T Konopaske; Darrick T Balu; Kendall T Presti; Grace Chan; Francine M Benes; Joseph T Coyle
Journal:  Schizophr Res       Date:  2018-05-11       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.